Results from MR analyses to estimate the effect of lipid-lowering therapies and risk factors on overall prostate cancer risk.

Effect estimates are odds ratios for prostate cancer per 1 SD reduction in LDL-c proxied using genetic instruments identified from the GLGC. In total, 28 genetic variants were used to proxy the inhibition of PCSK9, 4 for NPC1L1, 13 for HMGCR, 36 for the levels of LDLR-mediated LDL-c, and 424 for the levels of total LDL-c identified using the latest GLGC GWAS. F-statistics for the exposures ranges from 221.5 to 629.7. Detailed results can be found in S6 Table. GLGC, Global Lipids Genetics Consortium; LDL-c, LDL cholesterol; MR, Mendelian randomization; SD, standard deviation.